by lrevers | May 1, 2022 | Publications
Our new findings point to specific roles for the different domains of carcinoembryonic antigen. The human carcinoembryonic antigen (CEA) is a cell adhesion molecule involved in both homotypic and heterotypic interactions. The aberrant overexpression of CEA on...
by lrevers | Apr 21, 2022 | Publications
Read more about our scientists’ findings that MetVax can actively prevent tumor implantation, thereby blocking metastasis. Metastatic forms of cancers remain the main cause of death in cancer patients. In this study, we demonstrate that directing a sustained...
by lrevers | Apr 15, 2022 | Press Releases
D5Pharma’s groundbreaking new cancer vaccine, MetVax, capitalizes on a precisely defined protein fragment of carcinoembryonic antigen—a well-established mediator of adhesion and tumor implantation— to block metastasis. Read More
by lrevers | Apr 15, 2022 | Press Releases
Our team will be actively seeking partners for our technologies at BIO 2022 in San Diego, 13-16 June. Read About Us
by lrevers | Oct 10, 2021 | Press Releases
Our patented aptamers have demonstrated benefits in animal models of disease. D5Pharma’s lead drug candidate is PEG:CCS13, a PEGylated single-stranded DNA aptamer that is a selective agonist for the inflammatory modulator, CD200R1, a glycoprotein receptor found on the...
